5-(pentan-3-yl)benzo[d][1,3]dioxole | 108303-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-(pentan-3-yl)benzo[d][1,3]dioxole
• 英文别名: 5-Pentan-3-yl-1,3-benzodioxole
• CAS: 108303-56-6
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.258
• InChiKey: KGLPIMGNIFMRQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-溴戊烷 在 C₄₀H₅₅Cl₅N₃Pd 、 lithium chloride 作用下， 以 甲苯 为溶剂， 反应 5.91h， 生成 5-(pentan-3-yl)benzo[d][1,3]dioxole
  参考文献：
  名称：

  Pd-PEPPSI-IPentCl：高效的二级有机锌试剂选择性交叉偶联催化剂

  摘要：

  没有迁移吗？没问题！在芳基和杂芳基氯化物，溴化物和三氟甲磺酸与各种仲烷基锌试剂的Negishi交叉偶联中，已经创建并评估了一系列基于N杂环卡宾的新型Pd配合物（参见方案）。直接消除产物几乎是排他性的；在大多数示例中，根本没有迁移插入。

  DOI：

  10.1002/anie.201205747

文献信息

• Barbier-Negishi Coupling of Secondary Alkyl Bromides with Aryl and Alkenyl Triflates and Nonaflates
  作者：Ke-Feng Zhang、Fadri Christoffel、Olivier Baudoin

  DOI：10.1002/anie.201711990

  日期：2018.2.12

  secondary alkyl bromides with aryl and alkenyl triflates and nonaflates has been developed. This challenging reaction was enabled by the use of a very bulky imidazole‐based phosphine ligand, which resulted in good yields as well as good chemo‐ and site selectivities for a broad range of substrates at room temperature and under non‐aqueous conditions. This reaction was extended to primary alkyl bromides

  已经开发出温和而实用的仲烷基溴化物与芳基和烯基三氟甲磺酸酯和壬二酸酯的Barbier-Negishi偶联。通过使用非常庞大的咪唑基膦配体，可以实现这一具有挑战性的反应，从而在室温下和非水条件下对多种底物产生了良好的收率以及良好的化学和位点选择性。通过使用类似的吡唑基配体，该反应扩展为伯烷基溴化物。
• 5-(Arylsulfonyl)-Pyrazolopiperidines
  申请人：Ye Michael Xiaocong

  公开号：US20070155753A1

  公开（公告）日：2007-07-05

  The invention provides N-cyclic sulfonamido compounds of Formula I wherein A, B, R 1, R 1a, R 2 , R 2a, R 3 and R 3a are as described in the specification. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.

  本发明提供了式I的N-环磺酰胺化合物，其中A、B、R1、R1a、R2、R2a、R3和R3a如规范中所述。式I的化合物在治疗或预防认知障碍，如阿尔茨海默病方面是有用的。本发明还包括含有式I的制药组合物、制备式I化合物的方法，以及治疗认知障碍，如阿尔茨海默病的方法。
• BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES
  申请人：Huang Kenneth He

  公开号：US20110034529A1

  公开（公告）日：2011-02-10

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了I式化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4如所定义。I式化合物在治疗与细胞增殖相关的疾病和/或病情，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还公开了包含本发明化合物的药物组合物及使用这些化合物治疗上述疾病的方法。
• Compositions and methods for inhibition of the JAK pathway
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10556891B2

  公开（公告）日：2020-02-11

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  本文公开了式 I 的化合物、含有这些化合物的组合物，以及这些化合物和组合物用于治疗调节 JAK 通路或抑制 JAK 激酶（尤其是 JAK 2 和 JAK3）具有治疗作用的疾病的方法。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170158683A1

  公开（公告）日：2017-06-08

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.